The lack of strong molecular pathway activation due to that mutation suggests that JAK2 G517S is probably insufficient to trigger PV development and is unlikely to be the sole driver of abnormal erythropoiesis [51,53]. Here, JAK2 is linked to acquired polycythemia vera.